Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Injectables

    Jump to

    • Gland Pharma: Does it still offer value after a strong run?

      Though the management mentions that Cenexi has a decent clientele and the order book can be leveraged, an investment of 30 million euros is needed for its revamp

    • Concord Biotech: Time to take some profit off the table?

      The valuation of this leading fermentation play is now at a premium compared to the pharma sector, and there are new logistics challenges emerging for this export-heavy entity from the Red Sea crisis

    • Weekly Tactical Pick: A pharma stock that plays by the rulebook

    • Syngene: Multi-year contract with Zoetis adds to long-term visibility

    • Gland Pharma: What do acute supply shortages mean for the business & investors?

    • Gland Pharma: Track this inorganic play for the near term

    • Cadila: Unfolding vaccine opportunity can offset US headwinds

    • Aurobindo Pharma: Termination of inorganic bet eases capital allocation worries

    • Lupin: Margin guidance downgrade keeps us cautious

    • Cadila: More a COVID hedge in the near term

    • Glenmark Life Sciences IPO: Traction in complex APIs holds re-rating potential

    • Ideas For Profit | Gland Pharma: Steady earnings compounder; invest on dips

    • Gland Pharma’s new product play for FY22 holds a lot of promise

    • Aurobindo Pharma's board to consider demerger of its Injectables business soon

    • Lupin: New launches and market share gains are likely to override pricing erosion

    • Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate

    • Gland Pharma: Post IPO listing, what should investors do?

    • Gland Pharma IPO: Much more than a Heparin play; subscribe

    • Aurobindo Pharma: Shot in the arm for Covid vaccine development programme

    • Aurobindo: Traction in complex generics is vital to its health

    • Pfizer plans to bring more global drugs to India

    • Fosun Pharma best fit due to global presence, size: Gland Pharma

    • Citi bullish on Aurobindo Pharma; says stock can re-rate

    • Lupin scouts for acquisitions in US

    • Wockhardt hits 52-week low on UK import alert

      The UK drug regulator has issued an import alert on the company's Waluj plant near Aurangabad, which makes injectables and solid dosages. The US Food and Drug Administration had in May issued a similar import alert.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347